Furthermore, we found that GOLM1, lipopolysaccharide (LPS)-binding protein, XRCC6, and the contribution of neutrophil degranulation may play a crucial role in the development of therapies for BPD. This evidence concerns the gene XRCC6 and bronchopulmonary dysplasia.